Key result
Nitazoxanide interferes with SARS-CoV-2 spike maturation at an endoglycosidase H-sensitive stage, hindering progeny virion infectivity and spike-driven pulmonary cell-cell fusion across multiple variants.
Why the study?
The emergence of SARS-CoV-2 spike variants that facilitate viral spread and may impair vaccine efficacy highlighted the need for novel antiviral strategies.
Does nitazoxanide reduce SARS-CoV-2 spike maturation and fusion activity in vitro?
Does nitazoxanide reduce SARS-CoV-2 spike maturation and fusion activity in vitro?
Nitazoxanide demonstrates broad-spectrum in vitro antiviral activity against SARS-CoV-2 by impairing spike glycoprotein maturation and cell fusion, independent of emerging variants.
Answers are grounded in this paper and cite their sources.
In vitro activity across variants supports further preclinical testing; leaves open clinical efficacy and translation.
SARS-CoV-2, the causative agent of COVID-19, has caused an unprecedented global health crisis. The SARS-CoV-2 spike, a surface-anchored trimeric class-I fusion glycoprotein essential for viral entry, represents a key target for developing vaccines and therapeutics capable of blocking virus invasion. The emergence of SARS-CoV-2 spike variants that facilitate virus spread and may affect vaccine efficacy highlights the need to identify novel antiviral strategies for COVID-19 therapy. Here, we demonstrate that nitazoxanide, an antiprotozoal agent with recognized broad-spectrum antiviral activity, interferes with SARS-CoV-2 spike maturation, hampering its terminal glycosylation at an endoglycosidase H-sensitive stage. Engineering multiple SARS-CoV-2 variant-pseudoviruses and utilizing quantitative cell-cell fusion assays, we show that nitazoxanide-induced spike modifications hinder progeny virion infectivity as well as spike-driven pulmonary cell-cell fusion, a critical feature of COVID-19 pathology. Nitazoxanide, being equally effective against the ancestral SARS-CoV-2 Wuhan-spike and different emerging variants, including the Delta variant of concern, may represent a useful tool in the fight against COVID-19 infections.
No takes yet. Share an insight, caveat, or question.
Riccio et al. (2022) studied SARS-CoV-2 infection. Nitazoxanide vs. Vehicle was evaluated on SARS-CoV-2 spike maturation and fusion activity. Nitazoxanide interferes with SARS-CoV-2 spike maturation at an endoglycosidase H-sensitive stage, hindering progeny virion infectivity and spike-driven pulmonary cell-cell fusion across multiple variants.
Synapse has enriched 10 related papers. Consider them for comparative context: